Blue-Meds Biotechnology

Blue-Meds Biotechnology is a clinical-stage biopharmaceutical company based in Beijing, China, dedicated to developing innovative therapies for rare diseases, specifically lysosomal storage disorders. The company utilizes a proprietary protein engineering and modification platform to design next-generation enzyme replacement therapies (ERTs) that aim to improve upon the efficacy and safety of existing treatments. Its lead candidate, BM-001, is a recombinant human acid alpha-glucosidase currently in clinical development for the treatment of Pompe disease. By optimizing protein stability and cellular uptake, Blue-Meds seeks to address significant unmet medical needs in the global rare disease market. The company is backed by prominent venture capital firms and focuses on a bio-better strategy for metabolic genetic conditions.